Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) CFO Molly Henderson sold 2,110 shares of the stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $12.87, for a total transaction of $27,155.70. Following the transaction, the chief financial officer now directly owns 70,466 shares in the company, valued at $906,897.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Molly Henderson also recently made the following trade(s):
- On Thursday, April 6th, Molly Henderson sold 3,439 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $7.27, for a total transaction of $25,001.53.
- On Wednesday, March 1st, Molly Henderson sold 2,032 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.53, for a total transaction of $17,332.96.
Phathom Pharmaceuticals Price Performance
PHAT stock opened at $11.72 on Friday. Phathom Pharmaceuticals, Inc. has a twelve month low of $5.84 and a twelve month high of $14.45. The business’s 50-day simple moving average is $9.93 and its 200 day simple moving average is $9.79.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHAT. Quantbot Technologies LP raised its stake in shares of Phathom Pharmaceuticals by 112.6% in the second quarter. Quantbot Technologies LP now owns 5,527 shares of the company’s stock valued at $46,000 after acquiring an additional 2,927 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Phathom Pharmaceuticals by 20.1% in the second quarter. Legal & General Group Plc now owns 6,328 shares of the company’s stock valued at $54,000 after purchasing an additional 1,061 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Phathom Pharmaceuticals in the first quarter valued at approximately $81,000. Price T Rowe Associates Inc. MD acquired a new stake in Phathom Pharmaceuticals during the 2nd quarter worth $87,000. Finally, Credit Suisse AG acquired a new stake in Phathom Pharmaceuticals during the 2nd quarter worth $88,000. Institutional investors own 98.57% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Evercore ISI raised shares of Phathom Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Thursday, May 11th. Craig Hallum started coverage on Phathom Pharmaceuticals in a research report on Monday, March 13th. They issued a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 19th. Finally, BMO Capital Markets lowered their price target on Phathom Pharmaceuticals from $35.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Phathom Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $20.17.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
- Get a free copy of the StockNews.com research report on Phathom Pharmaceuticals (PHAT)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.